BI 1015550

Status
Phase 2
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Oral Drug
Funder Type
Industry

Drug Detail

BI 1015550 is a selective, phosphodiesterase 4b inhibitor under development for patients with IPF

Study Purpose

To investigate the efficacy of BI 1015550 compared to placebo based on the change from baseline in Forced Vital Capacity (FVC).

To investigate safety and tolerability of BI 1015550 in the overall trial population.

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >